Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$81.16 USD

81.16
7,966,400

+0.27 (0.33%)

Updated Sep 10, 2024 04:00 PM ET

After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication

AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.

Roche's (RHHBY) Application for PNH Drug Accepted by FDA

Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.

Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Kinjel Shah headshot

Medicare's First Price Negotiation List Targets Expensive Drugs

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca

Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.

Sanghamitra Saha headshot

Oncology Market's Huge Potential Puts These Stocks in Focus

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan

AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Emergent BioSolutions (EBS) Down 12% in a Week: Here's Why

Shares of Emergent (EBS) are on a downward trajectory since the ticker was dropped from the S&P SmallCap 600 index.

Pfizer's (PFE) RSV Vaccine Abrysvo Gets Approval in EU

Pfizer's (PFE) RSV vaccine, Abrysvo, gets approval in Europe to protect infants through maternal immunization as well as for older adults.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation

FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.

Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?

Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.

Pfizer's (PFE) RSV Vaccine Gets FDA Nod for Pregnant Women

The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for the prevention of lower respiratory tract disease in infants through administration to pregnant women.

Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca

Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article

Kinjel Shah headshot

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

Apellis (APLS) Focuses on Empaveli to Fuel Its Growth

Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, Syfovre faces some safety concerns post promising takeoff.

Is Most-Watched Stock AstraZeneca PLC (AZN) Worth Betting on Now?

Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates

Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises

Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.

Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised

Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.

Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View

Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

Company News for Jul 31, 2023

Companies in The News Are: XOM, INTC, PG, AZN

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales

AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.